全部

1·Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.

苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。

2·The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.

详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。

3·The tyrosine phosphorylated 130000 protein was identified as JAK2, a non receptor tyrosine kinase.

鉴定了分子量为130000酪氨酸磷酸化的蛋白质为JAK2，一种非受体型酪氨酸激酶。

4·HNMPA-AM3 -the insulin receptor tyrosine kinase inhibitor could block the anti-apoptosis effect of insulin.

胰岛素受体自身酪氨酸磷酸化抑制剂一一HNMPA一AM3可以阻断胰岛素的抗凋亡作用。

5·Objective: to establish a method of detecting insulin receptor tyrosine kinase (IRTK) activity from erythrocytes.

目的：建立红细胞胰岛素受体酪氨酸蛋白激酶(IRTK)的活性测定法。

6·Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma.

目的：研究散发型甲状腺髓样癌酪氨酸激酶受体基因（ RET）的突变情况。

7·Objective to investigate the change of insulin receptor tyrosine kinase (TK) activity in the pathogenesis of insulin resistance (IR).

目的探讨胰岛素受体酪氨酸激酶(TK)活性变化在胰岛素抵抗(IR)发生中的作用。

8·Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.

中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。

9·The phosphorylation assay proves that aldose reductase is the substrate of insulin-receptor tyrosine kinase and the Tyr(40) and Tyr(49) are phosphorylated by the kinase.

在试管内，未磷酸化的醛糖还原酶和磷酸化的醛糖还原酶的动力学常数无差异，而细胞内的情况有待于进一步研究。

10·Receptor tyrosine kinase-like orphan receptor-1 (ROR1) is expressed on sub-populations of B-cell malignancies and solid tumors, but not by healthy B cells or normal postpartum tissues.

受体酪氨酸激酶样孤儿受体1（ROR1）是在B-细胞恶性肿瘤和实体瘤亚群上表达的，但不在健康B细胞或正常产后组织中表达。